Elisabeth Framke, Poul Jørgen Jennum, Lau Caspar Thygesen, Melinda Magyari
{"title":"Sleep Disorders and Sleep Disturbances in Persons with Multiple Sclerosis: A Population-Based Matched Case-Control Study in Denmark.","authors":"Elisabeth Framke, Poul Jørgen Jennum, Lau Caspar Thygesen, Melinda Magyari","doi":"10.1159/000538307","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Adverse sleep is common in multiple sclerosis (MS). Population-based studies including adequate control groups are lacking. We hypothesized that the prevalence of sleep disorders and other sleep disturbances would be higher in persons with MS than in controls.</p><p><strong>Methods: </strong>We conducted a population-based study linking individual-level data from the Danish MS Registry (n = 21,943 persons with MS) and the Danish Population Registry (n = 109,715 matched controls) with information on sleep disorders from the Danish National Patient Registry and other sleep disturbances assessed by dispensed prescription drugs from the Danish National Prescription Registry.</p><p><strong>Results: </strong>Prevalence of diagnosed sleep disorders in terms of central hypersomnia (0.15% vs. 0.06%), sleep disturbances (1.05% vs. 0.70%), and sleep movements (0.22% vs. 0.13%) and other sleep disturbances identified by dispensed central acting (10.73% vs. 1.10%) and hypnotic use (30.65% vs. 20.13%) medication was statistically significantly higher among persons with MS when compared to controls. We found no statistically significant difference in the prevalence of sleep apnea and parasomnia between groups. Stratified by sex and age at MS diagnosis, results for differences between persons with MS and controls were similar.</p><p><strong>Conclusion: </strong>In this registry-based study, we found that the prevalence of several diagnosed sleep disorders was higher in persons with MS than in controls, that is, those reflecting insomnia and daytime symptoms including hypersomnia. Other sleep disturbances identified by dispensed prescription medication were markedly higher in persons with MS than in controls.</p>","PeriodicalId":54730,"journal":{"name":"Neuroepidemiology","volume":" ","pages":"335-341"},"PeriodicalIF":3.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroepidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538307","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Adverse sleep is common in multiple sclerosis (MS). Population-based studies including adequate control groups are lacking. We hypothesized that the prevalence of sleep disorders and other sleep disturbances would be higher in persons with MS than in controls.
Methods: We conducted a population-based study linking individual-level data from the Danish MS Registry (n = 21,943 persons with MS) and the Danish Population Registry (n = 109,715 matched controls) with information on sleep disorders from the Danish National Patient Registry and other sleep disturbances assessed by dispensed prescription drugs from the Danish National Prescription Registry.
Results: Prevalence of diagnosed sleep disorders in terms of central hypersomnia (0.15% vs. 0.06%), sleep disturbances (1.05% vs. 0.70%), and sleep movements (0.22% vs. 0.13%) and other sleep disturbances identified by dispensed central acting (10.73% vs. 1.10%) and hypnotic use (30.65% vs. 20.13%) medication was statistically significantly higher among persons with MS when compared to controls. We found no statistically significant difference in the prevalence of sleep apnea and parasomnia between groups. Stratified by sex and age at MS diagnosis, results for differences between persons with MS and controls were similar.
Conclusion: In this registry-based study, we found that the prevalence of several diagnosed sleep disorders was higher in persons with MS than in controls, that is, those reflecting insomnia and daytime symptoms including hypersomnia. Other sleep disturbances identified by dispensed prescription medication were markedly higher in persons with MS than in controls.
导言 多发性硬化症(MS)患者的不良睡眠很常见。目前还缺乏包括适当对照组在内的人群研究。我们假设,多发性硬化症患者的睡眠障碍和其他睡眠紊乱的患病率将高于对照组。方法 我们进行了一项基于人群的研究,将丹麦多发性硬化症登记处(21943 名多发性硬化症患者)和丹麦人口登记处(109715 名匹配对照组)的个人数据与丹麦全国患者登记处的睡眠障碍信息和丹麦全国处方登记处的处方药评估的其他睡眠障碍信息联系起来。结果 与对照组相比,多发性硬化症患者经诊断患有中枢性嗜睡(0.15% vs. 0.06%)、睡眠障碍(1.05% vs. 0.70%)和睡眠运动(0.22% vs. 0.13%)等睡眠障碍,以及通过配发中枢性作用药物(10.73% vs. 1.10%)和催眠药(30.65% vs. 20.13%)确定的其他睡眠障碍的患病率在统计学上明显更高。我们发现,睡眠呼吸暂停和寄生虫性失眠的患病率在不同组别之间没有明显的统计学差异。根据多发性硬化症诊断时的性别和年龄进行分层,多发性硬化症患者与对照组之间的差异结果相似。结论 在这项以登记为基础的研究中,我们发现多发性硬化症患者中几种确诊睡眠障碍的患病率高于对照组,即那些反映失眠和白天症状(包括嗜睡症)的睡眠障碍。与对照组相比,多发性硬化症患者通过配药处方发现的其他睡眠障碍也明显较高。
期刊介绍:
''Neuroepidemiology'' is the only internationally recognised peer-reviewed periodical devoted to descriptive, analytical and experimental studies in the epidemiology of neurologic disease. The scope of the journal expands the boundaries of traditional clinical neurology by providing new insights regarding the etiology, determinants, distribution, management and prevention of diseases of the nervous system.